Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adial Pharmaceuticals Inc ADIL

Healthcare
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is... see more

Recent & Breaking News (NDAQ:ADIL)

Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswire 7 days ago

Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 8 days ago

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

GlobeNewswire November 5, 2024

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

GlobeNewswire October 23, 2024

Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company's Genetic Diagnostic for Addiction Treatment

GlobeNewswire October 17, 2024

Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery

GlobeNewswire October 15, 2024

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswire September 19, 2024

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 4, 2024

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 14, 2024

Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

GlobeNewswire August 13, 2024

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswire August 7, 2024

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

GlobeNewswire July 31, 2024

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswire July 23, 2024

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

GlobeNewswire June 20, 2024

MicroCap Rodeo's Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies

Accesswire June 6, 2024

Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswire June 5, 2024

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

GlobeNewswire May 29, 2024

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 15, 2024

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

GlobeNewswire April 22, 2024

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

GlobeNewswire April 10, 2024